Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)
Transaction focused on Bylvay (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition
Albireo (ALBO) Acquired by Ipsen for $42/sh plus $10 CVR streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.